Genfit (NASDAQ:GNFT) Given “Buy” Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Genfit (NASDAQ:GNFT) in a research note issued to investors on Friday morning,Benzinga reports. HC Wainwright currently has a $13.00 target price on the stock.

Genfit Stock Down 2.1 %

Genfit stock opened at $3.91 on Friday. The company has a debt-to-equity ratio of 0.61, a current ratio of 3.74 and a quick ratio of 3.74. Genfit has a 1-year low of $3.35 and a 1-year high of $6.42. The company’s 50-day moving average is $3.76 and its 200 day moving average is $4.43.

Genfit Company Profile

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.